Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - acyclovir cream - cream - composition: acyclovir b.p. 5% w/w - antivirals for topical use

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - clidinium bromide and chlordiazepoxide tablets - coated tablet - each tablet cotains clidinium bromide 2.5mg and… - other drugs for peptic ulcer and

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - alprazolam 0.25mg tablet - tablet - each tablet contains 0.25mg alprazolam - alprazolam

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - alprazolam 0.5mg tablet - tablet - each tablet contains 0.5mg alprazolam - alprazolam

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - secnidazole - tablet - 1000mg per tablet - intestinal anti-infectives: imidazole derivatives

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - betamethasone and dexchlorpheniramine tablets - tablet - each tablet cotains betamethasone u.s.p 0.25mg… - combinations of antihistamines for systemic use:

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - paracetamol bp - tablet - 500mg/tablet - paracetamol

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - cetrizine hcl - syrup - 5mg per 5ml - other antihistamines for systemic use

Kenya - English - Pharmacy and Poisons Board

biopharmaltd 32547-00600 - cetrizine hcl - coated tablet - 10mg per tablet - other antihistamines for systemic use

United States - English - NLM (National Library of Medicine)

bionpharma inc. - dofetilide (unii: r4z9x1n2nd) (dofetilide - unii:r4z9x1n2nd) - dofetilide 0.125 mg - dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [af/afl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. because dofetilide can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. in general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. recurrence is expected in some patients (see clinical studies ). dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. dofetilide has not been shown to be effective in patients with paroxysmal atrial fibrillation. dofetilide is contraindicated in patients with congenital or acquired long qt syndromes. dofetilide should not be used in patients with a baseline